IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth
- 19 June 2007
- journal article
- clinical trial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (25) , 10589-10594
- https://doi.org/10.1073/pnas.0702031104
Abstract
Vessel loss precipitates many diseases. In particular, vessel loss resulting in hypoxia induces retinal neovascularization in diabetic retinopathy and in retinopathy of prematurity (ROP), major causes of blindness. Here we define insulin-like growth factor binding protein-3 (IGFBP3) as a new modulator of vascular survival and regrowth in oxygen-induced retinopathy. In IGFBP3-deficient mice, there was a dose-dependent increase in oxygen-induced retinal vessel loss. Subsequent to oxygen-induced retinal vessel loss, Igfbp3(-/-) mice had a 31% decrease in retinal vessel regrowth versus controls after returning to room air. No difference in serum insulin-like growth factor 1 (IGF1) levels was observed among groups. Wild-type mice treated with exogenous IGFBP3 had a significant increase in vessel regrowth. This correlated with a 30% increase in endothelial progenitor cells in the retina at postnatal day 15, indicating that IGFBP3 could be serving as a progenitor cell chemoattractant. In a prospective clinical study, we measured IGFBP3 (and IGF1) plasma levels weekly and examined retinas in all premature infants born at gestational ages , n = 13) was 802 microg/liter, and for infants with no ROP (ROP stage 0, n = 38) the mean level was 974 microg/liter (P < 0.03). These results suggest that IGFBP3, acting independently of IGF1, helps to prevent oxygen-induced vessel loss and to promote vascular regrowth after vascular destruction in vivo in a dose-dependent manner, resulting in less retinal neovascularization.Keywords
This publication has 30 references indexed in Scilit:
- IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular developmentProceedings of the National Academy of Sciences, 2007
- Dual effects of IGFBP‐3 on endothelial cell apoptosis and survival: Involvement of the sphingolipid signaling pathwaysThe FASEB Journal, 2004
- Insulin‐like growth factor binding protein‐3 is overexpressed in endothelial cells of mouse breast tumor vesselsInternational Journal of Cancer, 2002
- Changes in Insulin-like Growth Factor-Binding Protein-3 Messenger Ribonucleic Acid in Endothelial Cells of the Human Corpus Luteum: A Possible Role in Luteal Development and RescueJournal of Clinical Endocrinology & Metabolism, 2000
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Characterization of serum-derived and recombinant rat IGF-I and their use for measuring true concentrations of IGF-I in rat plasmaJournal of Endocrinology, 1996
- Insulin‐like growth factor‐binding protein enhancement of insulin‐like growth factor‐i (IGF‐I)–mediated DNA synthesis and IGF‐I binding in a human breast carcinoma cell lineJournal of Cellular Physiology, 1994
- Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.Journal of Clinical Investigation, 1993
- Microscopic Visualization of the Retina by Angiography with High-Molecular-Weight Fluorescein-Labeled Dextrans in the MouseMicrovascular Research, 1993
- Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblastsBiochemical and Biophysical Research Communications, 1988